WP1220 / Moleculin, WPD Pharma - LARVOL DELTA

Moleculin Reports Second Quarter 2021 Financial Results and Provides Programs Update (PRNewswire) - “H2 2021: File a US Investigative New Drug application (IND) for the treatment of certain adult cancer(s) with WP1066 and identify an institution to commence an associated investigator-funded Phase 1a/1B study…H2 2021: Continue support of the physician-sponsored pediatric brain tumor clinical trial.”

IND • Trial status • Brain Cancer • CNS Tumor • Oncology

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update (PRNewswire) - “First-in-class p-STAT3 inhibitors - WP1066 and WP1220 - Upcoming Milestones - 2H 2021: Facilitate Phase 1/2 study of WP1066 + radiation for the treatment of GBM. 1H 2022: Facilitate launch of Phase 2 study of WP1066 for the treatment of pediatric brain tumors, including DIPG. Actively seeking collaboration with a strategic partner in the near term for external funding for the continued development of WP1220 in a Phase 2 clinical trial as a topical therapy for CTCL…2H 2021: File an IND in the U.S. for the treatment of certain cancers such as GBM and pancreatic cancer, with WP1122.”

IND • Licensing / partnership • New P2 trial • Trial status • Cutaneous T-cell Lymphoma • Gastrointestinal Cancer • Glioblastoma • Hematological Malignancies • Non-Hodgkin’s Lymphoma • Oncology • Pancreatic Cancer

Moleculin Biotech, Inc. reports financial Results for the year ended December 31, 2019 (PRNewswire) - "Anticipated 2020 Milestones: IND submission for Annamycin for the treatment of tumor metastases to the lung, Pre-IND Meeting with FDA/EMA concerning a Phase 2 clinical trial with WP1220 for the treatment of CTCL, File IND/CTA for a Phase 2 clinical trial with WP1220 for the treatment of CTCL, FDA End of Phase 1 meeting for Annamycin in AML, Achieving an MTD or a dose level at or above 300 mg/m2 in EU AML Phase 1/2 trial for Annamycin." "

Clinical • FDA event • IND

Moleculin announces positive trial data with 100% safe delivery of p-STAT3 inhibitor and efficacy in majority of patients (PRNewswire) - "Moleculin Biotech, Inc...announced it now has preliminary data from its clinical trial of WP1220 for the treatment of cutaneous T-cell lymphoma...There were 6 patients screened, and 5 patients enrolled between March and July 2019....The only AE reported potentially related to study drug in one of the five patients was a mild contact dermatitis not requiring treatment. CAILS scores on index lesions were significantly decreased in the first 3 patients, who were stages IA, IB, and IIB, respectively, at entry."

Clinical data

Moleculin announces completion of lymphoma trial enrolment (PRNewswire) - “Moleculin Biotech, Inc….announced its proof of concept clinical trial to evaluate its p-STAT3 inhibitor, WP1220, for the topical treatment of Cutaneous T-Cell Lymphoma (CTCL) has reached full enrollment….we are hopeful to be able to announce results from this trial yet this year.”

Clinical data • Enrollment closed